QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lam, M. S. Articles by Sims-McCallum, R. P Search for Related Content PubMed PubMed Citation Articles by Lam, M. S. Articles by Sims-McCallum, R. P

HEMATOLOGY

Recombinant Factor VIIa in the Treatment of Non-Hemophiliac Bleeding

Clinical Pharmacy Specialist, Hematology/Oncology, Shands at the University of Florida, Gainesville, FL; Clinical Assistant Professor, College of Pharmacy, University of Florida

Rosalyn P Sims-McCallum, PharmD

Clinical Pharmacy Specialist, Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI

Reprints: Dr. Lam, PO Box 100316, Gainesville, FL 32610-0316, fax 352/338-9849, lamsh{at}shands.ufl.edu

OBJECTIVE: To review the clinical evidence for the use of recombinant factor VIIa (rFVIIa) in the prevention and/or treatment of bleeding in non-hemophiliac patients.

DATA SOURCES: A MEDLINE search (1966–December 2004) was conducted to identify pertinent literature. Results were limited to English-language reports and clinical trials. References of relevant articles and selected abstracts presented at scientific meetings were also reviewed.

STUDY SELECTION AND DATA EXTRACTION: Human data from prospective and retrospective studies that examined the hemostatic effect of rFVIIa in non-hemophiliac patients were reviewed, with a focus on surgical prophylaxis, liver disease, intractable bleeding associated with trauma and surgery, and anticoagulation reversal.

DATA SYNTHESIS: Results from limited controlled trials on the use of rFVIIa as an adjunct for prevention of bleeding in surgery and liver diseases have not been consistent. For treatment of intractable bleeding, earlier use of rFVIIa in one trauma trial was shown to decrease the number of blood transfusions, but no differences in terms of clinical outcomes were observed in all trials. Controlled trials do not suggest an increased risk of thrombotic events. Optimal dosing and timing of administration have yet to be defined.

CONCLUSIONS: Until further prospective controlled data are available, it is recommended that conventional intervention for prevention and control of hemorrhage in non-hemophiliac patients should remain the standard of care. Close monitoring of coagulation parameters is recommended before, during, and after therapy, especially in high-risk patients. Pharmacoeconomic analysis may be useful to help control costs and maximize clinical benefits.

Key Words: non-hemophiliac bleeding, recombinant factor VIIa

Published Online, March 22, 2005. www.theannals.com, DOI 10.1345/aph.1E553

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-016-H01

This article has been cited by other articles:

				S. J. Johnson, M. B. Ross, and K. G. Moores Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery Am. J. Health Syst. Pharm., September 1, 2007; 64(17): 1808 - 1812. [Abstract] [Full Text] [PDF]

				C. N. Rudisill, R. H. Hockman, K. A. Degregory, A. H. Mutnick, and B. G. Macik Implementing guidelines for the institutional use of factor VIIa (recombinant): A multidisciplinary solution. Am. J. Health Syst. Pharm., September 1, 2006; 63(17): 1641 - 1646. [Full Text] [PDF]